Materials & Resources » Chemicals | Hubei Biocause Pharmaceutical Co. Ltd.

Hubei Biocause Pharmaceutical Co. Ltd.

Hubei Biocause Pharmaceutical Co. Ltd. A
Stock Exchange Shenzhen Stock Exchange
EPS
CNY0.26
Market Cap
CNY31.52 B
Shares Outstanding
4.94 B
Public Float
1.54 B

Profile

Address
No. 132 Yangwan Road
Jingmen Hubei 448000
China
Employees -
Website http://www.biocause.com
Updated 07/08/2019
Hubei Biocause Pharmaceutical Co., Ltd. engages in the research, development, manufacture and sale of chemical products and medicinal raw materials. Its products include homatropine hydrobromide, thiotriazoline, lercanidipine hydrochloride, barnidipine hydrochloride, mitoxantrone hydrochloride, hyoscyamine sulfate, balsalazide sodium, oxaprozin, homatropine methyl bromide, flumazenil, milrinone, granisetron hydrochloride and others. The company was founded on November 18, 1993 and is headquartered in Jingmen, China.

Financials

View All
Created with Highcharts 5.0.14Hubei Biocause Pharmaceutical Co. Ltd. ANet Income. Fiscal year is January-December. All values CNY Millions.10110184842472471 7791 7791 3261 3261 3271 3272013201420152016201720180500100015002000
Created with Highcharts 5.0.14Hubei Biocause Pharmaceutical Co. Ltd. ASales/Revenue. Fiscal year is January-December. All values CNY Millions.96696680580553953916 19716 19753 09853 09830 11130 111201320142015201620172018010k20k30k40k50k60k

Shi Yan Wu
Chairman-Supervisory Board
Yi Qian Liu
Chairman